Travere Therapeutics (TVTX) News and press releases

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More

31 Jan 23

Biotech, News, Small Cap, FDA, Top Stories, General

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.

The Latest Analyst Ratings for Travere Therapeutics

30 Jan 23

Analyst Ratings

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $40

30 Jan 23

News, Price Target, Analyst Ratings

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $33 to $40.

Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $42

11 Jan 23

News, Price Target, Analyst Ratings

Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $38 to $42.

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022

14 Dec 22

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Stifel Initiates Coverage On Travere Therapeutics with Hold Rating, Announces Price Target of $22

14 Dec 22

News, Price Target, Initiation, Analyst Ratings

Stifel analyst Alex Thompson initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Hold rating and announces Price Target of $22.

Stocks That Hit 52-Week Lows On Monday

12 Dec 22

Options

Monday saw 196 companies set new 52-week lows.

4 Analysts Have This to Say About Travere Therapeutics

5 Dec 22

Analyst Ratings

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022

5 Dec 22

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Where Travere Therapeutics Stands With Analysts

5 Dec 22

Analyst Ratings

Wells Fargo Initiates Coverage On Travere Therapeutics with Overweight Rating, Announces Price Target of $28

5 Dec 22

News, Price Target, Initiation, Analyst Ratings

Wells Fargo initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Overweight rating and announces Price Target of $28.

Stocks That Hit 52-Week Lows On Tuesday

22 Nov 22

News, Options

During Tuesday's trading, 160 companies set new 52-week lows.

Travere Therapeutics to Present at Upcoming Investor Conferences

8 Feb 23

News, Press Releases

SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities Global Biopharma

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jan 23

Press Releases

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

3 Jan 23

News, Press Releases

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Dec 22

Press Releases

SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on December 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 Nov 22

Markets, Press Releases

SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants